| Literature DB >> 35847017 |
Nonvignon Murielle Codo Toafode1,2, Peter Marquardt3, Virgile Ahyi1, Karin Fester3, Verena Spiegler4, Cica Vissiennon2,5.
Abstract
In West African medicine, Entada africana Guill. & Perr. from the family of Fabaceae is used to treat inflammatory conditions in the management of fractures, wounds, and sprains in the northern region of the Republic of Benin. The aim of the present study was to isolate and elucidate phenolic compounds from a hydroalcoholic leaf extract from E. africana and to identify compounds with anti-inflammatory activity in vitro. Eleven compounds were purified from three fractions, which have shown strong to medium anti-inflammatory activity. The isolated compounds were characterized by HRESI-MS and NMR methods as gallic acid (1), ethyl gallate (2), 5,7-dihydroxychromen-4-one (3), 3',4',7-trihydroxyflavone (4), dihydrokaempferol-7-O-glucoside (5), catechin (6), quercetin-3-O-[β-apiosyl-(1‴→2″)-β-glucoside] (7), quercetin-3-O-glucoside (8), naringenin-7-O-glucoside (9), aromadendrin (10), and myricetin-3-O-glucoside (11). Nine of the major phenolic compounds were tested using TNF-α stimulated human keratinocytes (HaCaT) as skin inflammation model to identify molecules, which may explain the use of the plant leaves as an anti-inflammatory remedy by assessing the release of proinflammatory cytokines IL-8 and IL-6. The hydroacoholic leaf extract of E. africana exerted a medium inhibitory effect on the release of IL-8. 3',4',7-trihydroxyflavone, aromadendrin, dihydrokaempferol-7-O-glucoside and ethyl gallate demonstrated a strong to medium effect on the release of IL-6. For the release of IL-8, 3',4',7-trihydroxyflavone demonstrated a medium activity. This study provides for the first time a detailed screening of phenolic compounds occurring in the hydroethanolic leaf extract of E. africana. Additionally, it is shown that E. africana contains active compounds which may justify its traditional medicinal use as an anti-inflammatory remedy to treat inflammatory and pain-related skin conditions in the Republic of Benin.Entities:
Keywords: Entada africana; Republic of Benin; anti-inflammatory effect; phenolic compounds; traditional medicine
Year: 2022 PMID: 35847017 PMCID: PMC9280145 DOI: 10.3389/fphar.2022.931240
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
FIGURE 1Isolation pattern for compounds 1–11 from Entada africana leaves extract.
Summary of inhibitory effects of Entada africana leaf extract (Ea) and its fractions FC3, FC4, FC8, FC9, FC10, FC12, FC16, FC22 (1–100 µg/mL) on cytokine (IL-8, IL-6) release from TNFα-stimulated HaCaT cells.
| Mediator | Interleukin-8 (IL-8) | Interleukin-6 (IL-6) | ||
|---|---|---|---|---|
| Treatment | MI (%) | IC50 [95%CI] (µM) | MI (%) | IC50 [95% CI] (µM) |
| Ea | 48.1 ± 3.5 | 59.2 [36.1–97.0] | — | — |
| FC3 | 29.9 ± 3.6 | 55.3 [36.9–82.8] |
|
|
| FC4 | — | — | 56.2 ± 2.3 | 64.8 [18.9–222.9] |
| FC8 | 51.4 ± 1.9 | 36.9 [10.4–130.9] | 35 ± 6.5 | 148.6 [0.01 - 2e6] |
| FC9 | — | — | — | — |
| FC10 | — | — | — | — |
| FC12 | — | — | — | — |
| FC16 | — | — | — | — |
| FC22 |
|
| 57.8 ± 8.7 | 36.5 [7.1–187.2] |
MI, maximum inhibition, IC50, half maximal inhibitory concentration.
The values in bold represent: Fractions with a strong inhibitory effect (≥70%).
FIGURE 2Phenolic compounds isolated from Entada africana: Gallic acid (1), Ethyl gallate (2), 5,7-dihydroxychromone (3) and 3′,4′,7-trihydroxyflavone (4) from fraction FC3. Dihydrokaempferol-7-O- glucopyranoside (5) and catechin (6) from FC4-II, FC4-III yielded quercetin-3-O-[β-apiosyl-(1″→2″)-β-glucopyranoside] (7), isoquercitrin (8), prunin (9) and aromadendrin [syn. dihydrokaempferol (10)]. Myricetin-3-O-glucopyranoside (11) obtained from FC8.
Summary of inhibitory effects of Entada africana compounds 2-5 and 7–11 (0.1/1–100 µM) from cytokine (IL-8, IL-6) release from TNFα-stimulated HaCaT cells.
| Mediator | Interleukin-8 (IL-8) | Interleukin-6 (IL-6) | ||
|---|---|---|---|---|
| Treatment | MI (%) | IC50 [95%CI] (µM) | MI (%) | IC50 [95% CI] (µM) |
| Ethyl gallate ( | — | — | 42.5 ± 4.6 | 10.9 [6.8–17.3] |
| 5,7-dihydroxychromone ( | — | — | — | — |
| 3′,4′,7-trihydroxyflavone ( | 40.2 ± 5.1 | 126.2 [0.04–4.1e5] |
|
|
| Dihydrokaempferol-7- | — | — | 59.3 ± 5.8 | 7.4 [2.6–20.9] |
| Quercetin-3- | — | — | — | — |
| Quercetin-3- | 12.8 ± 3.7 | 66.0 [0.8–5.6e4] | — | — |
| Naringenin-7- | — | — | 28.5 ± 4.6 | 42.4 [26.6–67.5] |
| Aromadendrin ( | — | — | 67.0 ± 2.6 | 6 [4.1–8.8] |
| Myricetin-3- | 30 ± 7.9 | 184.1 [2.9e-7-1e11] | — | — |
MI, maximum inhibition, IC50, half maximal inhibitory concentration.
The values in bold represent: Single compounds with a strong inhibitory effect (≥70%).
FIGURE 3Influence of 3′,4′,7-trihydroxyflavone (1–100 µM) on TNF-α induced inflammatory mediator release from HaCaT cells (A). Influence on IL-6 release [pg/mL]; (B) concentration response curve for the inhibition of IL-6 release [% TNF-α control]; UC = untreated control, TNF = TNF-α stimulation and untreated control, Bud = TNF-α stimulation and budesonide 10 mM. Mean ± standard error of the mean (SEM), n = 4–6, significant ****p ≤ 0.0001, **p ≤ 0.01, and *p ≤ 0.05 compared to TNF-α treated cells ( = 100%) in ordinary 1-way ANOVA.